Leukemia Research Reports最新文献

{"title":"Acute liver failure and severe lactic acidosis as initial manifestations of primary intestinal diffuse large B-cell lymphoma: Case report","authors":"Hideki Mori ,&nbsp;Shiro Miura ,&nbsp;Momoko Soeda ,&nbsp;Yoshitaka Imaizumi","doi":"10.1016/j.lrr.2026.100574","DOIUrl":"10.1016/j.lrr.2026.100574","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) typically presents with lymphadenopathy or extranodal masses, but rarely, predominantly as scattered case reports, as acute liver failure (ALF) with severe lactic acidosis. We report a 79-year-old man who presented with fulminant ALF, leukemoid reaction, and extreme lactic acidosis. Despite intensive care, he rapidly progressed to multiorgan failure and died. Autopsy revealed primary intestinal DLBCL with diffuse hepatic infiltration. This case illustrates the diagnostic challenge in emergency settings and highlights the concept of a “metabolic catastrophe” characterized by ALF, leukemoid reaction, and lactic acidosis. Early recognition of these features should prompt consideration of invasive diagnostic procedures and suspicion for aggressive lymphoma.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100574"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An indian experience","authors":"Harish Pant ,&nbsp;Ajay Gogia ,&nbsp;Atul Sharma ,&nbsp;Naveet Wig ,&nbsp;Hari Krishna Raju Sagiraju ,&nbsp;Saumyaranjan Mallick ,&nbsp;Ritu Gupta ,&nbsp;Ahitagni Biswas","doi":"10.1016/j.lrr.2025.100554","DOIUrl":"10.1016/j.lrr.2025.100554","url":null,"abstract":"<div><h3>Background</h3><div>Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and comprises 9 % of total NHL in India. Rituximab maintenance (RM) after induction immunochemotherapy improves PFS. However, currently, no data exists from the Indian continent regarding the impact of Rituximab maintenance (RM) on overall survival (OS) &amp; progression-free survival (PFS). Our study aims to assess if RM improves the outcomes in FL patients.</div></div><div><h3>Methods</h3><div>This retrospective study included 95 patients diagnosed with FL meeting GELF criteria and registered at our institute All India Institute of Medical Sciences Delhi between January 2012 -December 2023. Among these, forty -four (46 %) patients received 2 years of RM every 2 months after induction immunochemotherapy. The primary outcome were overall survival (OS) and progression-free survival. Secondary outcomes were factors affecting OS &amp; PFS.</div></div><div><h3>Results</h3><div>Out of the 95 patients who met GELF criteria, 52 were male and 43 were female, with a median age of 53 years (range: 27–81). Advanced Ann Arbor stage III/IV comprises 82 (86 %) patients. Bone marrow involvement and bulky disease were observed in 36 (38 %) and 29 (31 %) patients respectively. Based on the Follicular Lymphoma International Prognostic Index (FLIPI-1), 27 (28 %) were low risk, 9 (10 %) intermediate risk, and 59 (62 %) were high risk. The complete remission (CR) was achieved in 71 % of patients. During follow-up, 27 (28 %) patients experienced relapsed and 8 patients transformed to diffuse large B-cell lymphoma (DLBCL). At a median follow-up of 63 months, the median OS was not reached. The median PFS was 122 months in the RM group and 94 months in the non-RM group, with 5-year PFS of 91.6 % vs 59.3 %, respectively (log-rank <em>p</em> = 0.017). Rituximab maintenance was independently associated with improved PFS (adjusted HR 0.28, 95 % CI: 0.12–0.65, <em>p</em> = 0.003). Failure to attain CR (aHR 2.49, 95 % CI: 1.20–5.19, <em>p</em> = 0.015) and bone marrow involvement (aHR 2.92, 95 % CI: 0.99–8.63, <em>p</em> = 0.05) were independently associated with inferior PFS.</div></div><div><h3>Conclusions</h3><div>Rituximab maintenance after induction immunochemotherapy significantly improved PFS. This is the first study from India demonstrating the impact of rituximab maintenance in FL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100554"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse","authors":"Donia Bouhoula ,&nbsp;Haifa Regaieg ,&nbsp;Hela Abroug ,&nbsp;Nesrine Ben Sayed ,&nbsp;Yossra Ben Youssef","doi":"10.1016/j.lrr.2025.100557","DOIUrl":"10.1016/j.lrr.2025.100557","url":null,"abstract":"<div><div>Treating pediatric acute myeloid leukemia in resource-limited settings presents unique therapeutic challenges. This study shares 19 years of experience from a Tunisian center, focusing on practical treatment outcomes. Our pediatric AML cohort (n=68) shows 50% initial remission rates (75% with idarubicin vs 31% novantrone) and 9% induction mortality. Despite salvage therapy (43% CR2), 5-year survival remained at 33%, constrained by high relapse (53%) and limited transplant access (21%). These results highlight critical needs: optimized frontline therapy and expanded salvage options for refractory cases.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100557"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country","authors":"Ha Thanh Nguyen ,&nbsp;Quoc Khanh Bach ,&nbsp;Quoc Nhat Nguyen ,&nbsp;Van Nam Nguyen ,&nbsp;Thi Van Anh Nguyen ,&nbsp;Hai Pham-The","doi":"10.1016/j.lrr.2026.100565","DOIUrl":"10.1016/j.lrr.2026.100565","url":null,"abstract":"<div><h3>Background</h3><div>Hypomethylating agents such as decitabine represent a key treatment option for elderly acute myeloid leukemia (AML) patients who are unfit for intensive chemotherapy. However, real-world evidence from low- and middle-income countries (LMICs), including Vietnam, remains scarce. This study aimed to identify baseline clinical and laboratory predictors of 1-year overall survival (OS) in elderly Vietnamese AML patients treated with decitabine.</div></div><div><h3>Methods</h3><div>This prospective, single-center, observational study was conducted at the National Institute of Hematology and Blood Transfusion, Vietnam, from April 2023 to June 2025. Seventy newly diagnosed AML patients aged ≥ 60 years received decitabine. The primary outcome was 1-year OS. Baseline demographic, clinical, hematologic, and immunophenotypic variables were analyzed using univariate and multivariate Cox regression. Treatment response was descriptively evaluated in patients completing ≥4 cycles.</div></div><div><h3>Results</h3><div>The 1-year OS rate was 38.6 %, with a median survival of 276.0 days. Elevated bone marrow cell count (HR: 1.003, <em>p</em> = 0.002), fibrinogen (HR: 1.22, <em>p</em> = 0.044), and urea (HR: 1.23, <em>p</em> = 0.001) were independently associated with increased mortality. CD64 positivity (HR: 0.29, <em>p</em> = 0.029) and urban residence (HR: 0.43, <em>p</em> = 0.014) were protective. Among 39 patients completing ≥4 cycles, 48.7 % achieved a complete response. No significant survival difference was observed between responders and non-responders.</div></div><div><h3>Conclusion</h3><div>This first prospective real-world study in Vietnam identified accessible predictors of survival in elderly AML patients receiving decitabine. The findings may aid early risk stratification using simple baseline parameters in LMIC settings, where access to molecular diagnostics may be limited, and warrant multicenter validation.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100565"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatitis induced by Peg-aspargase in children: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)","authors":"Wenwen Zhang ,&nbsp;Bin Luo ,&nbsp;Zhuo Liu ,&nbsp;Jie Mi ,&nbsp;Yanping Yang ,&nbsp;Yuan Li","doi":"10.1016/j.lrr.2026.100562","DOIUrl":"10.1016/j.lrr.2026.100562","url":null,"abstract":"<div><div>This study analyzed FAERS data to evaluate pegaspargase safety in pediatric acute lymphoblastic leukemia treatment. Among 21,161,817 reports, 847 identified pegaspargase as the primary suspect drug, revealing adverse events (AEs) across 26 organ systems. Disproportionality analysis identified four previously unlisted AEs. Critically, pegaspargase-associated pancreatitis incidence showed significant age-dependence (χ²=8.219, <em>p</em> &lt; 0.05). These findings address the knowledge gap in real-world, long-term pediatric safety profiles and provide crucial clinical references for safer medication use in children.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100562"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter’s syndrome","authors":"Tristan Meier ,&nbsp;Giovann Huynh ,&nbsp;Ernesto Ayala ,&nbsp;Han W. Tun ,&nbsp;Madiha Iqbal","doi":"10.1016/j.lrr.2026.100564","DOIUrl":"10.1016/j.lrr.2026.100564","url":null,"abstract":"<div><div>Richter’s syndrome (RS) is characterized by transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma. While significant treatment advances have been made in the management of CLL/SLL, current front-line management of RS is consistent with chemoimmunotherapy (CIT), a therapeutic approach adopted from the management of de-novo diffuse large B-cell lymphoma (DLBCL). In de-novo DLBCL, CIT alone can potentially cure a significant percentage of patients; however in RS, outcomes with CIT alone are particularly poor. Therefore there is a significant unmet need to improve the current standard of care for the management of RS. We present a case of a patient with newly diagnosed RS who was treated with a novel upfront combination of CIT and a Bruton tyrosine kinase inhibitor, resulting in excellent long-term outcomes. We also present accompanying literature review highlighting other anecdotal cases reported with similar therapeutic approach and discuss emerging treatment strategies in the management of RS.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100564"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning models in predictive factors for megaloblastic character of macrocytic anemia","authors":"Melek Kechida ,&nbsp;Mohamed Kenani ,&nbsp;Nader Slama ,&nbsp;Manel Mili ,&nbsp;Aminetou Salem ,&nbsp;Wassim Krit ,&nbsp;Ines Khochtali ,&nbsp;Sarra Boukhris ,&nbsp;Asma Ben Abdallah ,&nbsp;Mohamed Hedi Bedoui","doi":"10.1016/j.lrr.2026.100568","DOIUrl":"10.1016/j.lrr.2026.100568","url":null,"abstract":"<div><h3>Background</h3><div>Differentiating megaloblastic from non-megaloblastic macrocytic anemia usually relies on vitamin B12 and/or B9 assessment and bone marrow examination. In resource-limited regions, these diagnostic tools are not readily available. This study aims to develop a machine learning model to distinguish between these two forms of macrocytic anemia using commonly accessible clinical and laboratory parameters.</div></div><div><h3>Methods</h3><div>A logistic regression model was developed using a dataset containing clinical features and routine laboratory data. Key predictive variables were identified through the SequentialFeatureSelector. The model was optimized using GridSearchCV and validated through stratified 5-fold cross-validation to ensure robust performance.</div></div><div><h3>Results</h3><div>ESR, glossitis, and MCHC were the most influential variables in predicting non-megaloblastic anemia, with respective importance percentages of 23.11 %, 22.07 %, and 13.87 %. Other variables such as LDH (13.77 %), aregenerative status (13.42 %), and limb paresthesia (11.78 %) also contributed significantly to the model, while MCV had a comparatively lower importance (1.98 %). The model demonstrated a high discriminatory ability, with an area under the ROC curve (AUC) of 0.92 and an overall accuracy of 94 %. Learning curve analysis confirmed its stability and consistent performance across varying data sizes.</div></div><div><h3>Conclusions</h3><div>By reducing dependence on specialized diagnostic tests and invasive procedures, this approach is particularly suited for resource-constrained healthcare settings.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100568"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147395027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aplastic anaemia with small paroxysmal nocturnal haemoglobinuria clones developing during osimertinib therapy for non-small cell lung cancer","authors":"Hayata Morimoto ,&nbsp;Seiichiro Katagiri ,&nbsp;Tomokazu Omori ,&nbsp;Shunsuke Otsuki ,&nbsp;Seiichiro Yoshizawa ,&nbsp;Nahoko Furuya ,&nbsp;Hiroaki Fujimoto ,&nbsp;Hironori Takeuchi ,&nbsp;Akihiko Gotoh ,&nbsp;Daigo Akahane","doi":"10.1016/j.lrr.2026.100572","DOIUrl":"10.1016/j.lrr.2026.100572","url":null,"abstract":"<div><div>We report two cases of aplastic anaemia (AA) with small populations of paroxysmal nocturnal haemoglobinuria (PNH)-phenotype cells that developed during osimertinib (OSIM) therapy for epidermal growth factor receptor mutation-positive lung adenocarcinoma (EGFR-LUAD). The first case was a 76-year-old woman with EGFR-LUAD accompanied by pleural dissemination. She developed pancytopenia 9 months after starting OSIM therapy. We diagnosed the patient with moderately severe AA and observed hematopoietic recovery following treatment with anabolic steroids and eltrombopag. The second case involved a 63-year-old woman diagnosed with EGFR-LUAD who received adjuvant chemotherapy with OSIM. She developed pancytopenia 6 months later and was diagnosed with non-severe AA. Cyclosporine and romiplostim treatment were effective, allowing for outpatient management. In the two cases described herein, a small number of PNH-phenotype cells were confirmed. The clinical importance of the small PNH-phenotype populations and the mechanism underlying AA during OSIM therapy remain unclear and warrant further investigation.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100572"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147395028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma","authors":"Vincent T. Taillefer ,&nbsp;Marianne Emond ,&nbsp;Marie-Hélène Leblanc ,&nbsp;Stephane Doucet ,&nbsp;Jean-Philippe Adam","doi":"10.1016/j.lrr.2026.100566","DOIUrl":"10.1016/j.lrr.2026.100566","url":null,"abstract":"<div><h3>Introduction</h3><div>A combination of Gemcitabine, Dexamethasone and Cisplatin (GDP) with or without rituximab (±R) is an outpatient treatment widely used for relapsed or refractory (R/R) lymphoma. Limited data are available on stem cell mobilization following GDP treatment.</div></div><div><h3>Method</h3><div>A retrospective multicenter study was conducted from January 1st, 2014, to December 31st, 2020. Patients received GDP±R before autologous stem cell transplantation (ASCT) and were mobilized with either GDP±R or intermediate-dose cyclophosphamide (ID-CY). The primary objective was to determine the percentage of patients achieving ≥2 × 10⁶ CD34⁺/kg, median CD34⁺ yield, and number of apheresis days. The secondary objective compared these results with ID-CY.</div></div><div><h3>Results</h3><div>Ninety-two patients (median age 54) were treated for diffuse large B-cell (40%), Hodgkin (36%), or follicular lymphoma (16%). Of these, 83 were mobilized with GDP±R and 9 with ID-CY. G-CSF was administered at 5 mcg/kg (61%) or 10 mcg/kg (37%) daily, typically starting on day 9, after two GDP cycles. A successful stem cell collection at the first attempt occurred in 96% of GDP±R patients, and 94% of patients proceeded to ASCT. No significant difference was found between GDP±R and ID-CY in terms of successful collection (96% vs. 100%, <em>p</em>=NS), but fewer hospitalizations occurred within 21 days of mobilization (1% vs. 22%, <em>p</em> = 0.02).</div></div><div><h3>Conclusion</h3><div>This study demonstrated the feasibility of performing a peripheral blood stem cell mobilization at day 15 following GDP±R. It is highly effective and represents a better option due to its simplicity of administration, low rate of hospitalization and low cost.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100566"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of variant acute promyelocytic leukemia with FIP1L1-RARA fusion gene: case report and literature review","authors":"Yanyan Qiu,&nbsp;Huarong Zhou,&nbsp;Shaoyuan Wang","doi":"10.1016/j.lrr.2025.100553","DOIUrl":"10.1016/j.lrr.2025.100553","url":null,"abstract":"<div><div>Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the promyelocytic leukemia-retinoic acid receptor alpha (<em>PML-RARA</em>) fusion gene and exceptional responsiveness to differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (Arsenic Trioxide). However, rare variant forms of APL involving alternative <em>RARA</em> fusion partners, such as <em>FIP1L1-RARA</em>, are typically resistant to ATRA/ATO-based regimens and are associated with poor clinical outcomes. We report a rare case of <em>FIP1L1-RARA</em>-positive APL in a patient who initially presented with clinical, morphological, and immunophenotypic features consistent with classical APL. Standard diagnostic evaluations, including morphology, flow cytometry, and fluorescence in situ hybridization (FISH), failed to detect the fusion abnormality. The diagnosis was ultimately confirmed by RNA sequencing (RNA-Seq). Empirical induction with ATRA and ATO was initiated but resulted in persistent and progressive promyelocytosis. Anthracycline-based chemotherapy was subsequently administered, followed by azacitidine combined with venetoclax in the subsequent course of treatment. Although partial hematologic improvement was observed, the overall response remained suboptimal. This case underscores the diagnostic challenges of atypical APL and highlights the pivotal role of RNA-Seq in identifying cryptic <em>RARA</em> rearrangements. A literature review suggests that <em>FIP1L1-RARA</em>-positive APL represents a biologically and clinically distinct entity with highly variable treatment responses and poor prognosis. Early molecular diagnosis and prompt implementation of conventional chemotherapy or targeted therapies such as venetoclax may be essential to improving outcomes in this rare APL subtype.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100553"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145625109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}